居裡 CRIS 深 滬
已收盤 09-20 16:00:00 美东时间
5.91
-0.020
-0.34%
華盛通- 最 高5.95
- 今 開5.85
- 成交量 1.76万股
- 最 低 5.75
- 昨 收 5.93
- 總市值 3483.41万
- 52周最高 17.49
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 3.80
- 委 比 36.61%
- 總股本 589.41万
- 歷史最高 565.00
- 量 比 0.31
- 振 幅 3.37%
- 歷史最低 4.0516
- 每 手 1
- 風險率 3.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多面对13.42万名患者，放射配体疗法能否带来“新曙光”？
21世纪经济报道记者武瑛港 实习生孙航星 北京报道 “在前列腺癌诊疗领域，对于放射配体疗法的进一步发展，寻求MDT即多学科协作是关键，需要让泌尿外科和核医学科共...
09-14 18:27
自爆！千亿市值超级独角兽，把自己“作死”了
10年前，贵为基因疗法“独角兽”的蓝鸟生物，是投资人眼中的香饽饽，但如今，手握3个天价商业化产品的蓝鸟，却被扔进了“垃圾桶”，市值仅剩1亿美元出头。 撰文...
08-22 20:24
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination wit...
08-13 20:05
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:AP...
08-08 20:05
Revenues Working Against Curis, Inc.'s (NASDAQ:CRIS) Share Price Following 36% Dive
Unfortunately for some shareholders, the Curis, Inc. (NASDAQ:CRIS) share price ...
08-08 19:16
Curis Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
08-02 04:16
Buy Rating Affirmed for Curis on Strong Financials and Promising Emavusertib Trials
H.C. Wainwright analyst Edward White maintained a Buy rating on Curis (CRIS – R...
08-01 23:35
Curis Q2 2024 GAAP EPS $(2.03) Misses $(1.67) Estimate, Sales $2.546M Beat $2.064M Estimate
Curis (NASDAQ:CRIS) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.67) by 21.56 percent. This is a 17.81 percent increase over losses of $(2.47) per share from the same
08-01 20:02
